Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression
about
Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior?The role of monoamine oxidase inhibitors in current psychiatric practiceA brief history of the development of antidepressant drugs: from monoamines to glutamateInhibitors of MAO-A and MAO-B in Psychiatry and NeurologyWorld Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.Monoamine oxidase A upregulated by chronic intermittent hypoxia activates indoleamine 2,3-dioxygenase and neurodegeneration.Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients.Current place of monoamine oxidase inhibitors in the treatment of depression.MAOIs - does the evidence warrant their resurrection?World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants.The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor.A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression.Bipolar depression: diagnostic and treatment considerations.Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities."Ping-pong gaze" secondary to monoamine oxidase inhibitor overdose.Xanthoangelol and 4-Hydroxyderricin Are the Major Active Principles of the Inhibitory Activities against Monoamine Oxidases on Angelica keiskei K.Selegiline transdermal system: a novel treatment option for major depressive disorder.Atypical depression: useful concept, but it's time to revise the DSM-IV criteria.The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?The hidden third: improving outcome in treatment-resistant depression.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Critical appraisal of selegiline transdermal system for major depressive disorder.The Black Book of Psychotropic Dosing and Monitoring.Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case.Practical guide for prescribing MAOIs: debunking myths and removing barriers.[Developmental process of DGPPN quality indicators].Treatment and Prevention of Depression.Expression of recombinant human flavin monooxygenase and moclobemide-N-oxide synthesis on multi-mg scale.
P2860
Q24621858-CC3BCA4C-FC7A-45AF-B874-D3AE79A228BBQ24679460-7BEAEE43-FBFE-4AD9-A50E-1F9683ADEDB3Q27028050-C12D1374-C722-4641-820C-A145771B0FA4Q28069609-793616E5-E0E7-4FAC-95F7-E9F7AAF6050DQ31121208-FF265AE0-DBA4-4313-8F6E-6CA4974A9912Q33708210-BE1C67AF-C9F5-4CEA-995F-202DAE2C80E7Q33784147-0BE5B2C3-057E-427B-810C-4B41A82DD970Q34052523-67FBF5EB-16A8-46F1-95B8-6C9C0981663EQ34363276-E1F68861-5CFD-4426-A200-AF52473130A2Q34515817-33EB6B17-17BE-47C6-87FE-3FF996F51B3DQ34578945-6A0ECBEE-2D91-4A72-A147-9D00130600E8Q34590910-9B200DB1-4E85-470E-8A6E-220E006B80D0Q34867111-75158800-6E32-4C0C-BC5F-39572F1E6E71Q36244817-48693DF5-C1F1-45A7-AF93-8AF477639E64Q36474119-55E1919A-D74F-4B32-ACF3-E78F89A4D8A8Q36634433-50B7C5D9-6085-42AF-BEB1-EF56EDA427F2Q36637666-880E43DC-60FC-4EF3-9A61-46E7036E31E1Q36797716-C970F482-CA79-4589-B85A-9A0B2F88AEBDQ37314132-83898433-C4E9-46B0-9E28-CBFFF04221EDQ37519729-CFF78584-295B-4B91-84E5-EF46BCED0127Q37594567-F2C4AFC8-FD10-460D-8CA1-A358F11B5AD3Q37941518-092C812B-6050-4F0A-ACFF-CD1BAFF5D9F0Q37974998-73C722FF-8334-4203-9C95-4EC4460B4AE6Q38123516-84763EFD-6CED-4A4B-BD32-09766966EF16Q38268523-4CFAEF66-528B-4252-9E18-335ED7E0127FQ38720525-1BE00E09-BF91-49D5-830C-2E464D35D1D6Q47642128-40D971F5-F83F-4018-9A7E-0CF95096A550Q48074026-54BD72D5-2C7D-4C46-A956-17BF88DF4337Q48645946-5400EC46-7894-4B1C-92EA-A6D4C2C0D9B4Q50754002-3380C77D-1F6F-4F13-A7AB-8864DDF781F6Q52009697-0115B5E1-227E-4343-B13A-868E5689273FQ54336662-15AC302F-E8AA-463A-923D-6886451E5DD1
P2860
Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Meta-analysis of the reversibl ...... or the treatment of depression
@ast
Meta-analysis of the reversibl ...... or the treatment of depression
@en
Meta-analysis of the reversibl ...... or the treatment of depression
@nl
type
label
Meta-analysis of the reversibl ...... or the treatment of depression
@ast
Meta-analysis of the reversibl ...... or the treatment of depression
@en
Meta-analysis of the reversibl ...... or the treatment of depression
@nl
prefLabel
Meta-analysis of the reversibl ...... or the treatment of depression
@ast
Meta-analysis of the reversibl ...... or the treatment of depression
@en
Meta-analysis of the reversibl ...... or the treatment of depression
@nl
P2093
P3181
P1476
Meta-analysis of the reversibl ...... or the treatment of depression
@en
P2093
F Lotufo-Neto
P304
P3181
P356
10.1016/S0893-133X(98)00075-X
P407
P577
1999-03-01T00:00:00Z
P6179
1051722205